EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Experimental and Computational Discovery of the Oxazole–Thiadiazole–Sulfonamide Hybrids as Dual α-Amylase and α-Glucosidase Inhibitors

Fakhria A. Al-Joufi, Hayam A. Alwabsi, Syed Shujait Ali, Bandar K. Baothman, Naif Alsuhaymi, Mahdi H. Alsugoor, Inam Ur Rahman, Mengue Ngadena Yolande Sandrine, Metab Alharbi

Pharmaceuticals · 14.11.2026 · 19 (11) · 1808

DOI: 10.3390/ph19111808 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 14.11.2026. Verfasst von Fakhria A. Al-Joufi und 8 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Saud University.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diabetes mellitus (DM) is a major global health concern. Inhibition of α-amylase and α-glucosidase is an established approach to controlling postprandial glucose levels. In this study, we aimed to synthesize oxazole–thiadiazole–sulphonamide derivatives (1–14) and evaluate their inhibitory activity against both enzymes.

Methods

Fourteen derivatives were synthesized and characterized using 1H NMR, 13C NMR, and high-resolution electron ionization mass spectrometry (HR-EI-MS). Their inhibitory activities were evaluated using acarbose as the reference inhibitor. Structure–activity relationship (SAR) analysis and molecular docking studies were performed to investigate the influence of aromatic substitution and explore potential enzyme–ligand interactions.

Results

Compound 5 had the strongest inhibitory activity, displaying values of IC50 6.20 ± 0.30 µM for α-amylase and 6.70 ± 0.20 µM for α-glucosidase, in comparison with 10.50 ± 0.20 µM and 11.10 ± 0.30 µM, respectively, for acarbose. The other derivatives showed varying inhibitory activities. Docking analysis provided computational insights into possible interactions within the enzyme binding sites.

Conclusions

Compound 5 was the most potent derivative in the series against both enzymes and represents a promising in vitro candidate for further biochemical, mechanistic, and safety evaluation.

Förderung

  • King Saud University

Zitieren

APA

Al-Joufi, F. A., Alwabsi, H. A., Ali, S. S., Baothman, B. K., Alsuhaymi, N., Alsugoor, M. H., Rahman, I. U., Sandrine, M. N. Y., & Alharbi, M. (2026). Integrated Experimental and Computational Discovery of the Oxazole–Thiadiazole–Sulfonamide Hybrids as Dual α-Amylase and α-Glucosidase Inhibitors. Pharmaceuticals, 19(11), 1808. https://doi.org/10.3390/ph19111808

Vancouver

Al-Joufi FA, Alwabsi HA, Ali SS, Baothman BK, Alsuhaymi N, Alsugoor MH, et al. Integrated Experimental and Computational Discovery of the Oxazole–Thiadiazole–Sulfonamide Hybrids as Dual α-Amylase and α-Glucosidase Inhibitors. Pharmaceuticals. 2026;19(11):1808. doi:10.3390/ph19111808

BibTeX
@article{AlJoufi2026,
  author = {Al-Joufi, Fakhria A. and Alwabsi, Hayam A. and Ali, Syed Shujait and Baothman, Bandar K. and Alsuhaymi, Naif and Alsugoor, Mahdi H. and Rahman, Inam Ur and Sandrine, Mengue Ngadena Yolande and Alharbi, Metab},
  title = {Integrated Experimental and Computational Discovery of the Oxazole–Thiadiazole–Sulfonamide Hybrids as Dual α-Amylase and α-Glucosidase Inhibitors},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {11},
  pages = {1808},
  doi = {10.3390/ph19111808}
}
Kostenlos starten →